Industry Reports

Vivus, a developer of therapies to address obesity, sleep apnea, diabetes and male sexual health, has reported the data of Qnexa in its Phase 3 study.Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase...

Novartis' net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by 8% as the US dollar weakened against most currencies. Recently launched products grew 46% over the previous-year quarter, contributing USD 3.8 billion to total...

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended March...

ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation announced today a total revenue increase of 94% for the first quarter of 2011. ELC Group published their annual results in January and predicted a gain in net revenues for the...

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended 31st March 2011. Profit after tax but before Exceptional Item grew by 16%. While the overall sales grew by 11.4%, net sales of the pharmaceuticals business...

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended 31st March 2011. Profit after tax but before Exceptional Item grew by 16%. While the overall sales grew by 11.4%, net sales of the pharmaceuticals business...

Impax Laboratories, Inc.reported first quarter ended March 31, 2011 financial results. Larry Hsu, Ph.D., president and CEO, Impax Laboratories, Inc. said, Our revenue related to the sale of our generic and brand products and services other than generic Flomax(R)...